Warning: Pradaxa And The Potential Risk Of Fatal Bleeding

We’ve previously warned you about the dangers linked to the blood thinning drug Pradaxa (Dabigatran)… and despite the fact that even medical experts were against its approval, this potentially dangerous drug is still on the market.

In fact, the mainstream seems to ignore all the stark warnings against taking this drug and it is now being prescribed to countless unsuspecting patients despite reports of thousands of serious bleeding events and many deaths associated with the drug.

All the risk with little reward

If you’re taking the blood thinner Pradaxa to treat your atrial fibrillation (A-Fib), you could have a much higher risk for major (and potentially fatal) intestinal bleeding that may skyrocket immediately.

According to a study, published in JAMA Internal Medicine, when researchers compared the two blood thinning drugs Pradaxa and Warfarin, they found Pradaxa “… was consistently associated with an increased risk of major bleeding and gastrointestinal haemorrhage.”

However, when the American Food and Drug Administration (FDA) rolled out the red carpet for Pradaxa in 2010, the agency called Pradaxa a ‘lifesaver’ and fast tracked the potentially risky drug amongst a lot of hype about it being the next step in blood thinners since it needed less monitoring and maintenance than Warfarin.

But that appears to be a lie. Pradaxa caused 542 people to bleed to death, in 2011 alone.

In a press release, JAMA Internal Medicine‘s editor-in-chief said ‘the whole Pradaxa experience reminded him of the need to continue tracking drugs after they hit the market.’

Well, actually, agencies like the FDA should stop fast-tracking drugs, because if we really want to save lives, how about adequately testing ALL drugs before they hit the market.

Fast-tracking drugs turn us into unwilling guinea pigs for Big Pharma, and the consequences can be potentially deadly.

In a 2011 report, the FDA even had the nerve to boast about speeding Pradaxa through a fast-tracked six-month review. But whenever they resort to this mad scramble for approval, safety questions get kicked down the road to be answered in future trials.

Drug companies know this, so they put safety issues on the back burner – or worse, they hide the potential dangers.

As we told you a few months ago, the Pradaxa data submitted to the FDA wasn’t just inadequate – drug company minions apparently deliberately buried vital information, putting every single user in the last four years at even greater risk.

Perhaps someday someone in their right mind will dump this insanely dangerous fast-tracking system into the junk yard of bad ideas and replace it with strict safety requirements before approval. But until then we’ll have to protect ourselves.

Any time your doctor prescribes a new medication for you do your research. If it’s a new fast-tracked drug refuse to become a test subject in Big Pharma’s latest drug experiment. Instead ask your doctor to recommend a safer alternative.

And if you’re already taking Pradaxa talk to your doctor about safer ways to combat atrial fibrillation.

---

Disclaimer: Bear in mind the material contained in this article is provided for information purposes only. We are not addressing anyone’s personal situation. Please consult with your own physician before acting on any recommendations contained herein.

---

Sources:

Risk of Bleeding With Dabigatran in Atrial Fibrillation, archinte.jamanetwork.com

FY 2011 Innovative Drug Approvals, fda.gov

Dabigatran Associated with Higher Incidence of Major Bleeding vs. Warfarin, media.jamanetwork.com

Study of Drug for Blood Clots Caused a Stir, Records Show, nytimes.com